Latest Insider Transactions at Pfizer Inc (PFE)
This section provides a real-time view of insider transactions for Pfizer Inc (PFE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PFIZER INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PFIZER INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 26
2020
|
Douglas M Lankler Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
90,417
-14.66%
|
$3,164,595
$35.41 P/Share
|
|
Feb 26
2020
|
Douglas M Lankler Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
34,175
+13.23%
|
-
|
|
Feb 26
2020
|
Douglas M Lankler Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
88,567
+31.8%
|
$3,011,278
$34.59 P/Share
|
|
Feb 26
2020
|
Dawn Rogers Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
12,774
-26.77%
|
$447,090
$35.76 P/Share
|
|
Feb 26
2020
|
Dawn Rogers Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,097
+37.66%
|
$513,298
$34.59 P/Share
|
|
Feb 26
2020
|
Sally Susman Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
72,253
-12.73%
|
$2,528,855
$35.41 P/Share
|
|
Feb 26
2020
|
Sally Susman Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
22,783
+10.08%
|
-
|
|
Feb 26
2020
|
Sally Susman Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
72,464
+28.64%
|
$2,463,776
$34.59 P/Share
|
|
Feb 26
2020
|
John D Young Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
145,425
-9.31%
|
$5,089,875
$35.41 P/Share
|
|
Feb 26
2020
|
John D Young Group President |
BUY
Grant, award, or other acquisition
|
Direct |
45,566
+7.66%
|
-
|
|
Feb 26
2020
|
John D Young Group President |
BUY
Exercise of conversion of derivative security
|
Direct |
144,928
+22.34%
|
$4,927,552
$34.59 P/Share
|
|
Feb 26
2020
|
Alexander R Mackenzie Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
16,088
-7.04%
|
$546,992
$34.72 P/Share
|
|
Feb 26
2020
|
Alexander R Mackenzie Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
38,289
+14.96%
|
-
|
|
Feb 23
2020
|
Angela Hwang President, Global Biopharma |
SELL
Payment of exercise price or tax liability
|
Direct |
1,409
-7.27%
|
$49,315
$35.72 P/Share
|
|
Feb 23
2020
|
Dawn Rogers Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,015
-9.3%
|
$35,525
$35.72 P/Share
|
|
Feb 23
2020
|
Michael Goettler Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,116
-7.68%
|
$74,060
$35.72 P/Share
|
|
Feb 23
2020
|
Loretta V Cangialosi Sr. Vice President, Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
1,574
-1.45%
|
$55,090
$35.72 P/Share
|
|
Jan 31
2020
|
Lidia Fonseca Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,043
-12.24%
|
$223,591
$37.24 P/Share
|
|
Jan 30
2020
|
Scott Gottlieb Director |
BUY
Open market or private purchase
|
Direct |
1,000
+20.0%
|
$37,000
$37.0 P/Share
|
|
Dec 29
2019
|
John D Young Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
9,676
-2.63%
|
$377,364
$39.32 P/Share
|
|
Dec 16
2019
|
John D Young Group President |
SELL
Bona fide gift
|
Direct |
1,280
-0.35%
|
-
|
|
Nov 29
2019
|
Angela Hwang President, Global Biopharma |
SELL
Bona fide gift
|
Indirect |
216
-2.47%
|
-
|
|
Nov 27
2019
|
Loretta V Cangialosi Sr. Vice President, Controller |
SELL
Bona fide gift
|
Direct |
660
-0.61%
|
-
|
|
Aug 30
2019
|
Angela Hwang President, Global Biopharma |
BUY
Discretionary transaction
|
Indirect |
9,896
+43.07%
|
$346,360
$35.55 P/Share
|
|
Aug 23
2019
|
Scott Gottlieb Director |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$102,000
$34.72 P/Share
|
|
Jul 02
2019
|
Frank A Damelio Executive Vice President |
SELL
Open market or private sale
|
Direct |
153,184
-1.84%
|
$6,740,096
$44.1 P/Share
|
|
Jun 20
2019
|
Alexander R Mackenzie Executive Vice President |
SELL
Open market or private sale
|
Direct |
30,000
-27.25%
|
$1,320,000
$44.0 P/Share
|
|
May 29
2019
|
Angela Hwang President, Global Biopharma |
SELL
Bona fide gift
|
Indirect |
240
-2.67%
|
-
|
|
Apr 29
2019
|
Dawn Rogers Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
4,255
-28.52%
|
$165,945
$39.59 P/Share
|
|
Apr 01
2019
|
Alexander R Mackenzie Executive Vice President |
SELL
Open market or private sale
|
Direct |
15,000
-0.55%
|
$630,000
$42.8 P/Share
|
|
Mar 15
2019
|
Rady A Johnson Executive Vice President |
SELL
Open market or private sale
|
Direct |
8,700
-12.7%
|
$356,700
$41.13 P/Share
|
|
Mar 04
2019
|
Sally Susman Executive Vice President |
SELL
Open market or private sale
|
Direct |
72,723
-0.86%
|
$3,127,089
$43.23 P/Share
|
|
Mar 04
2019
|
Ian C Read Executive Chairman |
SELL
Open market or private sale
|
Direct |
580,866
-0.74%
|
$24,977,238
$43.29 P/Share
|
|
Mar 04
2019
|
Dawn Rogers Executive Vice President |
SELL
Open market or private sale
|
Direct |
15,002
-26.03%
|
$630,084
$42.99 P/Share
|
|
Mar 04
2019
|
Mikael Dolsten President R&D |
SELL
Open market or private sale
|
Direct |
49,082
-2.98%
|
$2,110,526
$43.54 P/Share
|
|
Mar 01
2019
|
Mikael Dolsten President R&D |
SELL
Open market or private sale
|
Direct |
100,471
-5.99%
|
$4,320,253
$43.58 P/Share
|
|
Mar 01
2019
|
Mikael Dolsten President R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
106,191
+11.42%
|
$3,291,921
$31.41 P/Share
|
|
Feb 28
2019
|
Lidia Fonseca Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
47,510
+50.0%
|
-
|
|
Feb 28
2019
|
Loretta V Cangialosi Sr. Vice President, Controller |
BUY
Grant, award, or other acquisition
|
Direct |
3,482
+3.11%
|
-
|
|
Feb 27
2019
|
Albert Bourla Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
51,770
-8.02%
|
$2,174,340
$42.62 P/Share
|
|
Feb 27
2019
|
Albert Bourla Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
64,322
+16.23%
|
$2,058,304
$32.23 P/Share
|
|
Feb 27
2019
|
Albert Bourla Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
96,183
+26.44%
|
-
|
|
Feb 27
2019
|
Loretta V Cangialosi Sr. Vice President, Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
24,635
-6.66%
|
$1,034,670
$42.72 P/Share
|
|
Feb 27
2019
|
Loretta V Cangialosi Sr. Vice President, Controller |
BUY
Grant, award, or other acquisition
|
Direct |
8,017
+5.82%
|
-
|
|
Feb 27
2019
|
Loretta V Cangialosi Sr. Vice President, Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
25,729
+17.45%
|
$823,328
$32.23 P/Share
|
|
Feb 27
2019
|
Frank A Damelio Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
193,784
-10.3%
|
$8,138,928
$42.72 P/Share
|
|
Feb 27
2019
|
Frank A Damelio Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
96,183
+12.32%
|
-
|
|
Feb 27
2019
|
Frank A Damelio Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
182,247
+23.66%
|
$5,831,904
$32.23 P/Share
|
|
Feb 27
2019
|
Mikael Dolsten President R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
73,773
-9.49%
|
$3,098,466
$42.93 P/Share
|
|
Feb 27
2019
|
Mikael Dolsten President R&D |
BUY
Grant, award, or other acquisition
|
Direct |
96,183
+19.14%
|
-
|